Amgen Patents for Cholesterol Drug Repatha Upheld by Jury
- Jurors reject claims of inadequacy by Sanofi and Regeneron
- Repatha and competing drug Praluent are for ultra-high LDL
This article is for subscribers only.
A U.S. jury upheld two patents for Amgen Inc.’s cholesterol-lowering drug Repatha, dealing a blow to Sanofi and Regeneron Pharmaceuticals Inc., which make a similar medication called Praluent.
Billions of dollars in anticipated sales for the competing drugs are at stake in the latest chapter in a legal fight that began in 2014 and included a rare sales ban on Praluent that ultimately was vacated. Repatha alone, which treats extremely high levels of “bad” cholesterol, is expected to bring in $2.21 billion in 2022.